{"ticker": {"uuid": "ef4c035b-44bb-414d-bfdb-21633e1da884", "symbol": "SNGX", "name": "Soligenix Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Soligenix (SNGX) seeks reverse stock split, higher share authorization to protect Nasdaq listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQTnZJTjVtYlhFRnpTTlNlT19OMkxJQjRPOVFSSjBGZmdDSzZXaVh0Nk5qRUtlcHQ2aVRXTWdIbmI1OGs5M09HVVhDV2tyNzBTMnh5Tkd3Qkk0VXBZTzkxcEdpRnFkS1NWWmJzM19yV1BTNlpwSmtELUJYMDJuWGh1c2RHTElaYV9senZnUE9PNXVVMDR0czlRVUM4X0FSOTBnYUdmeWgwOHA1dUI3TE1PTw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T20:41:03+00:00", "published_display": "21 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Soligenix, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides access to Soligenix, Inc.'s SEC filings and other corporate documents, including Forms 10-K, 10-Q, and 8-K. It details earnings reports and corporate presentations from 2022 through Q1 2026, highlighting key financial outcomes, clinical program updates, and str", "url": "https://www.tradingview.com/symbols/BOATS-SNGX/documents/", "source_name": "TradingView", "published_at": "2026-07-01T11:10:43", "published_display": "01 Jul 2026 11:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Expands At-the-Market Equity Offering Capacity", "summary": "Soligenix Inc. has increased its At Market Issuance Sales Agreement with Rodman & Renshaw LLC by an additional $2.5 million, bringing the total amount available under the offering to over $8.7 million. This expansion allows Soligenix to continue raising capital through equity off", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SNGX/pressreleases/3017405/soligenix-expands-at-the-market-equity-offering-capacity/", "source_name": "The Globe and Mail", "published_at": "2026-06-27T20:40:53", "published_display": "27 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Soligenix Inc For: 26 June", "summary": "The article reports on the filing of Form 424B5 by Soligenix Inc. for June 26, as published by Investing.com. It contains a disclaimer about the high risks associated with trading financial instruments and cryptocurrencies, emphasizing that the data provided is not necessarily re", "url": "https://m.uk.investing.com/news/stock-market-news/form-424b5-soligenix-inc-for-26-june-93CH-4746850?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-27T07:40:53", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Soligenix, Inc. \u2013 NASDAQ:SNGX", "summary": "This article provides financial information for Soligenix, Inc. (NASDAQ: SNGX), specifically its forward price-to-sales ratio. It references data from TradingView, FactSet, and ICE Data Services. The content indicates the market was closed at the time of publication and that no t", "url": "https://www.tradingview.com/symbols/NASDAQ-SNGX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:11:25", "published_display": "27 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Soligenix Inc For: 26 June By Investing.com", "summary": "This article from Investing.com reports on a Form 424B5 filing by Soligenix Inc. The filing is dated for June 26. The article itself is very brief, mainly serving as a notification about the filing with financial market data and popular news links surrounding it.", "url": "https://za.investing.com/news/stock-market-news/form-424b5-soligenix-inc-for-26-june-93CH-4346287", "source_name": "Investing.com South Africa", "published_at": "2026-06-27T05:10:21", "published_display": "27 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix ups ATM offering by $2.5M under Rodman & Renshaw agreement", "summary": "Soligenix (SNGX) has increased its at-the-market (ATM) issuance capacity by $2.5 million under its existing sales agreement with Rodman & Renshaw. This expansion follows previous sales totaling approximately $6.234 million against a prior capacity of $6.406 million. The company f", "url": "https://www.tradingview.com/news/tradingview:921a13276c6db:0-soligenix-ups-atm-offering-by-2-5m-under-rodman-renshaw-agreement/", "source_name": "TradingView", "published_at": "2026-06-26T20:09:32", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix (NASDAQ: SNGX) resets ATM capacity to $2.5M under S-3", "summary": "Soligenix, Inc. (NASDAQ: SNGX) has amended its At-The-Market (ATM) sales agreement, resetting its capacity to $2.5 million under its Sales Agreement with Rodman & Renshaw LLC. This update, filed via a 424B5 prospectus supplement, replaces previously unsold amounts and is constrai", "url": "https://www.stocktitan.net/sec-filings/SNGX/424b5-soligenix-inc-prospectus-supplement-debt-securities-6d08b8bcaab8.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:32", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix (NASDAQ: SNGX) adds $2.5M to at-the-market stock program", "summary": "Soligenix, Inc. (NASDAQ: SNGX) has increased its at-the-market stock program capacity by $2.5 million through a new prospectus supplement. This allows the company to issue and sell more common stock through its existing sales agreement with Rodman & Renshaw LLC. The company had p", "url": "https://www.stocktitan.net/sec-filings/SNGX/8-k-soligenix-inc-reports-material-event-3cac49908639.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:32", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Michael Liu, MJL Manager (SNGX) disclose 983,588 shares; related group holds material blocks", "summary": "Michael Liu, MJL Manager LLC, and Capuchin Capital Fund LP have disclosed their beneficial ownership of SOLIGENIX, INC. (SNGX) shares via a Schedule 13G filing. Michael Liu reports beneficial ownership of 983,588 shares (5.7%), while MJL Manager LLC holds 893,588 shares (5.2%), a", "url": "https://www.stocktitan.net/sec-filings/SNGX/schedule-13g-soligenix-inc-passive-investment-disclosure-5-deb7c3dfdae9.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:32", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix, Inc. Actuals & Estimates (NASDAQ:SNGX)", "summary": "This article provides a detailed financial overview and analyst estimates for Soligenix, Inc. (NASDAQ:SNGX), covering its stock price performance, forecasts, historical highs and lows, volatility, market capitalization, earnings, and revenue. It also addresses frequently asked qu", "url": "https://www.tradingview.com/symbols/NASDAQ-SNGX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:40:44", "published_display": "25 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNGX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Soligenix, Inc. (SNGX) stock for 2027, based on analyst opinions. It includes financial data, past performance, and answers frequently asked questions about the company's stock, such as its current price, volatility, market ca", "url": "https://www.tradingview.com/symbols/NASDAQ-SNGX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:40:32", "published_display": "25 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Soligenix, Inc. \u2013 NASDAQ:SNGX", "summary": "The article mentions the enterprise value to revenue forward for Soligenix, Inc. (NASDAQ: SNGX). It appears to be a financial data point from TradingView, which often provides various financial metrics for stocks. The content indicates this specific metric is related to Soligenix", "url": "https://www.tradingview.com/symbols/NASDAQ-SNGX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T13:11:48", "published_display": "25 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Inc (SNGX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Soligenix Inc (SNGX) stock information, focusing on its dividend history and stock split events. It highlights that the company has not distributed dividends in the past five years and details several merger-related stock splits, primarily in ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sngx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-21T21:09:13", "published_display": "21 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Inc (SNGX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Soligenix Inc (SNGX), highlighting its current earnings forecast score of 8.00 and an average price target of $17.50, based on one analyst's \"Buy\" rating. It details the upside potential, recent EPS performance, and expected next-qua", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sngx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T13:10:40", "published_display": "18 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Inc (SNGX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Soligenix Inc (SNGX), noting its current financial score is 6.59, ranking 238 out of 388 in the Biotechnology & Medical Research industry. It identifies the company's financial status as robust but its operating efficiency as low. Cru", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sngx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:49", "published_display": "18 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Inc (SNGX) Institutional Confidence", "summary": "This article provides an overview of the institutional confidence in Soligenix Inc (SNGX), noting its stock price, market cap, and various financial scores from TradingKey. It details institutional shareholding and shareholder activity, highlighting changes in shares held by seve", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sngx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T00:10:12", "published_display": "17 Jun 2026 00:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNGX - Soligenix Inc Stock Price and Quote", "summary": "This page provides a detailed financial overview and news compilation for Soligenix Inc. (SNGX), a late-stage biopharmaceutical company focusing on rare diseases. It includes stock performance data, key financial metrics, recent analyst ratings, and a chronological list of news e", "url": "https://finviz.com/stock?t=SNGX", "source_name": "Finviz", "published_at": "2026-06-16T11:11:32", "published_display": "16 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix's Richard C. Straube ceases Consulting CMO role; duties moved to Christopher Pullion", "summary": "Richard C. Straube has ended his role as Consulting Chief Medical Officer for Soligenix on June 11, 2026. His responsibilities have been transferred to Medical Director Christopher Pullion. This change occurred due to the company's decision to terminate its HyBryte\u2122 development p", "url": "https://www.tradingview.com/news/tradingview:9b7b379d5df25:0-soligenix-s-richard-c-straube-ceases-consulting-cmo-role-duties-moved-to-christopher-pullion/", "source_name": "TradingView", "published_at": "2026-06-12T20:09:14", "published_display": "12 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Received Notice of Noncompliance", "summary": "Soligenix (SNGX) received a notice from Nasdaq on June 10, 2026, indicating noncompliance with the minimum bid price requirement for having its stock trade below $1.00 for 30 consecutive business days. The company has 180 days, until December 7, 2026, to regain compliance, with a", "url": "https://www.tradingview.com/news/tradingview:1e5416fa10a7b:0-soligenix-received-notice-of-noncompliance/", "source_name": "TradingView", "published_at": "2026-06-12T20:09:13", "published_display": "12 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix (NASDAQ: SNGX) faces Nasdaq bid-price risk and ends HyBryte program", "summary": "Soligenix (NASDAQ: SNGX) announced the termination of its HyBryte\u2122 development program following an interim analysis of its Phase 3 trial that recommended stopping due to futility, resulting in an estimated $70,000 in wind-down costs. Concurrently, the company received a Nasdaq w", "url": "https://www.stocktitan.net/sec-filings/SNGX/8-k-soligenix-inc-reports-material-event-f9a176781f43.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:13", "published_display": "12 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 8, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Stock Short Interest Rises to 43.99%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNLXBicmxhclFTUXZZbERRSWU3SnB2Smh5aWpndzhheWdUbjNadUEzd1lZcEI0amUwLWR1X3p2MmVyNXVUUTFzcHRvMUVFVUtCRjY2ZnNqT0VIbUJnVFlYRXEzSUotdlNsN1NtUEQ3LXltM0FXcGU0anpmNk1pS3lNdVg2YXJJek9M?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine", "summary": "Soligenix, Inc. is applying for vaccine development funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for a Bundibugyo virus (BDBV) vaccine. The company, in collaboration with Dr. Axel Lehrer of the University of Hawai\u02bbi at M\u0101noa, has developed thermostable ", "url": "https://www.prnewswire.com/news-releases/soligenix-applying-for-vaccine-development-funding-for-bundibugyo-ebola-vaccine-302793388.html", "source_name": "PR Newswire", "published_at": "2026-06-08T11:39:17", "published_display": "08 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Expands At-The-Market Equity Financing Capacity", "summary": "Soligenix, a biopharmaceutical company, has increased its At-The-Market (ATM) equity financing capacity by an additional $2,956,000, following previous sales of approximately $3,445,000 under the same program. This move allows Soligenix greater financial flexibility for its opera", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SNGX/pressreleases/2210014/soligenix-expands-at-the-market-equity-financing-capacity/", "source_name": "The Globe and Mail", "published_at": "2026-05-31T07:40:54", "published_display": "31 May 2026 07:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix, Inc. Files SEC Form 8-K for May 28, 2026 \u2013 Company Information and Legal Exhibits", "summary": "Soligenix, Inc. filed an 8-K with the SEC announcing an increase in its At Market Issuance Sales Agreement with Rodman & Renshaw LLC by $2,956,000, bringing the total to $6,406,000. This move, approved by the Board of Directors, aims to raise capital but also introduces potential", "url": "https://www.minichart.com.sg/2026/05/29/soligenix-inc-files-sec-form-8-k-for-may-28-2026-company-information-and-legal-exhibits/", "source_name": "Minichart", "published_at": "2026-05-29T14:39:42", "published_display": "29 May 2026 14:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix (NASDAQ: SNGX) raises at-the-market stock capacity by $2.96M", "summary": "Soligenix (NASDAQ: SNGX) has increased its at-the-market stock offering capacity by an additional $2.96 million through a prospectus supplement. This expands an existing sales agreement with Rodman & Renshaw LLC, under which the company had previously sold approximately $3.445 mi", "url": "https://www.stocktitan.net/sec-filings/SNGX/8-k-soligenix-inc-reports-material-event-01d174282f19.html", "source_name": "Stock Titan", "published_at": "2026-05-28T21:38:57", "published_display": "28 May 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix (NASDAQ: SNGX) raises ATM ceiling to $2.96M under Sales Agreement", "summary": "Soligenix, Inc. has updated its at-the-market (ATM) offering capacity to $2.96 million for common stock under a Sales Agreement with Rodman & Renshaw LLC. This adjustment is based on a public float of $24.51 million and aligns with General Instruction I.B.6 of Form S-3. The compa", "url": "https://www.stocktitan.net/sec-filings/SNGX/424b5-soligenix-inc-prospectus-supplement-debt-securities-38724fd96b27.html", "source_name": "Stock Titan", "published_at": "2026-05-28T21:38:57", "published_display": "28 May 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix raises at\u2011market share capacity by $2.956M under sales agreement", "summary": "Soligenix (SNGX) has increased the maximum amount of common stock available for sale under its at-market sales agreement by $2,956,000. This follows a prospectus supplement filed on May 28, 2026. The company had previously sold approximately $3,445,000 of common stock under the s", "url": "https://www.tradingview.com/news/tradingview:d789be717e178:0-soligenix-raises-at-market-share-capacity-by-2-956m-under-sales-agreement/", "source_name": "TradingView", "published_at": "2026-05-28T21:38:57", "published_display": "28 May 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Soligenix (SNGX.US)$ small win but consistent so far.", "summary": "An investor, Delmas W, shared a brief post on the Moomoo community platform noting a \"small win but consistent so far\" with Soligenix (SNGX.US). The post was part of a discussion thread titled \"Share Your Profit/Loss.\" The content itself is very minimal, serving more as a comment", "url": "https://www.moomoo.com/community/feed/soligenix-sngx-us-small-win-but-consistent-so-far-116648049311749", "source_name": "Moomoo", "published_at": "2026-05-28T05:39:44", "published_display": "28 May 2026 05:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix more than doubles as traders react to Ebola-outbreak vaccine-platform update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNU0Q3UXpIR0J4M08xOXhoSmVWYVdiRWZSYUc0SmQ5UW5SUGQyWjlKQTlYVTIybEk2WWtmYzl0aUFpY2I2YTJYS1pqSFNOMVdlZUJCUnBjNHk0YkJyV2FEb042R3JESHlUbk1DZmhMbzQ2OTR2TEd1b1kyTEcxQkRWZDNSRDNvYWlFcHFacTJBeWFYempWQWQ3bVZsUktQRzJBWlBNUkRRSzItZ3JWZ2NWWTFTTjYzYTFPazY4?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Soligenix Announces Recent Updates and First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/soligenix-announces-recent-updates-first-113000061.html", "source_name": "PR Newswire", "published_at": "2026-05-08T11:30:00+00:00", "published_display": "08 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte\u2122 in Treatment of Cutaneous T-Cell Lymphoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/soligenix-announces-interim-results-phase-113000458.html", "source_name": "PR Newswire", "published_at": "2026-04-28T11:30:00+00:00", "published_display": "28 Apr 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial \u2014 Traders Eye Multiday Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQTGoxWFZIWEdHUFZlc3QwYnAzQ2oySUpsU2JXMncxWjhMLUJrUm9HajNORVEtM2lqREJjRTF1NkRjLVFtMGlrcHlyd3h3VmxTajdlQ0ZjQ3MyeHVCWjdqNjlkUURPMVBSVGF3UXFXNF9OWlhsR3pBTUxzS0JKa2FOeDBMRVNFR0hDdnFfUUNZNV9OdExIMjJNN2J4WG1nSUd3bHhkLW4taVdmTGgxYUg3cDNiN0NpS2dHZEhhcnJrV0ZiVmg3WkEwTGJFRGdhQnJEd2V6THZGd1FtWmI5ejQ4?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Announces Pricing of $7.5 Million Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPMlVTVE1xR0JJSlh4bWNVV2djVmNCcHBQM29fc3lvamctYnM5NFZPZjhmMkVYMmZRZWF1ajFzNE9rQVlXaldrYTZOWV82M0laZkpySUZQZTF2U3FVWGdDdmVVZy1PVjRXWG45WG9XVW9fWUY0X0hCUFJrLVFBWmk3WnNST0N0c01pVHFLQmhybk1tckctMnlUd3drMmk3bUE4ZUdHRmFaZHBnSU1YTHNZOGRlZU4?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-26T07:00:00+00:00", "published_display": "26 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNaldSR2VuTFVVbTBaY0pSWlI0RFdoLXVTNi1jaDh3cXZSdGJLWk5QMXJWRDhaZERXRXAxZHB6VThXWDgxTVJzV0lRYlJyMGJNN29jM1lySmZObElBQkhtOVo3M1hMWEV3enU0dUR3bjlfcGxQRGZNYURZYm9xemM3VFRsdzB4NW5Gc0tF?oc=5", "source_name": "Market source", "published_at": "2025-08-20T07:00:00+00:00", "published_display": "20 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix (SNGX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9LZjZrcURQeHRDMXcwdWxwZkFsQjZ6SWxRVzlPU1NJR3pUb0poa2tLTHJhbVFnSmc5V2IwYy1Kdm5rLXVXSkRoV3lOUUYwVDgzR1VJ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:42:21+00:00", "published_display": "25 Apr 2025 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Soligenix (SNGX) seeks reverse stock split, higher share authorization to protect Nasdaq listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQTnZJTjVtYlhFRnpTTlNlT19OMkxJQjRPOVFSSjBGZmdDSzZXaVh0Nk5qRUtlcHQ2aVRXTWdIbmI1OGs5M09HVVhDV2tyNzBTMnh5Tkd3Qkk0VXBZTzkxcEdpRnFkS1NWWmJzM19yV1BTNlpwSmtELUJYMDJuWGh1c2RHTElaYV9senZnUE9PNXVVMDR0czlRVUM4X0FSOTBnYUdmeWgwOHA1dUI3TE1PTw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T20:41:03+00:00", "published_display": "21 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides access to Soligenix, Inc.'s SEC filings and other corporate documents, including Forms 10-K, 10-Q, and 8-K. It details earnings reports and corporate presentations from 2022 through Q1 2026, highlighting key financial outcomes, clinical program updates, and str", "url": "https://www.tradingview.com/symbols/BOATS-SNGX/documents/", "source_name": "TradingView", "published_at": "2026-07-01T11:10:43", "published_display": "01 Jul 2026 11:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Expands At-the-Market Equity Offering Capacity", "summary": "Soligenix Inc. has increased its At Market Issuance Sales Agreement with Rodman & Renshaw LLC by an additional $2.5 million, bringing the total amount available under the offering to over $8.7 million. This expansion allows Soligenix to continue raising capital through equity off", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SNGX/pressreleases/3017405/soligenix-expands-at-the-market-equity-offering-capacity/", "source_name": "The Globe and Mail", "published_at": "2026-06-27T20:40:53", "published_display": "27 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Soligenix Inc For: 26 June", "summary": "The article reports on the filing of Form 424B5 by Soligenix Inc. for June 26, as published by Investing.com. It contains a disclaimer about the high risks associated with trading financial instruments and cryptocurrencies, emphasizing that the data provided is not necessarily re", "url": "https://m.uk.investing.com/news/stock-market-news/form-424b5-soligenix-inc-for-26-june-93CH-4746850?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-27T07:40:53", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Soligenix, Inc. \u2013 NASDAQ:SNGX", "summary": "This article provides financial information for Soligenix, Inc. (NASDAQ: SNGX), specifically its forward price-to-sales ratio. It references data from TradingView, FactSet, and ICE Data Services. The content indicates the market was closed at the time of publication and that no t", "url": "https://www.tradingview.com/symbols/NASDAQ-SNGX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:11:25", "published_display": "27 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Soligenix Inc For: 26 June By Investing.com", "summary": "This article from Investing.com reports on a Form 424B5 filing by Soligenix Inc. The filing is dated for June 26. The article itself is very brief, mainly serving as a notification about the filing with financial market data and popular news links surrounding it.", "url": "https://za.investing.com/news/stock-market-news/form-424b5-soligenix-inc-for-26-june-93CH-4346287", "source_name": "Investing.com South Africa", "published_at": "2026-06-27T05:10:21", "published_display": "27 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix ups ATM offering by $2.5M under Rodman & Renshaw agreement", "summary": "Soligenix (SNGX) has increased its at-the-market (ATM) issuance capacity by $2.5 million under its existing sales agreement with Rodman & Renshaw. This expansion follows previous sales totaling approximately $6.234 million against a prior capacity of $6.406 million. The company f", "url": "https://www.tradingview.com/news/tradingview:921a13276c6db:0-soligenix-ups-atm-offering-by-2-5m-under-rodman-renshaw-agreement/", "source_name": "TradingView", "published_at": "2026-06-26T20:09:32", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix (NASDAQ: SNGX) resets ATM capacity to $2.5M under S-3", "summary": "Soligenix, Inc. (NASDAQ: SNGX) has amended its At-The-Market (ATM) sales agreement, resetting its capacity to $2.5 million under its Sales Agreement with Rodman & Renshaw LLC. This update, filed via a 424B5 prospectus supplement, replaces previously unsold amounts and is constrai", "url": "https://www.stocktitan.net/sec-filings/SNGX/424b5-soligenix-inc-prospectus-supplement-debt-securities-6d08b8bcaab8.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:32", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix (NASDAQ: SNGX) adds $2.5M to at-the-market stock program", "summary": "Soligenix, Inc. (NASDAQ: SNGX) has increased its at-the-market stock program capacity by $2.5 million through a new prospectus supplement. This allows the company to issue and sell more common stock through its existing sales agreement with Rodman & Renshaw LLC. The company had p", "url": "https://www.stocktitan.net/sec-filings/SNGX/8-k-soligenix-inc-reports-material-event-3cac49908639.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:32", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Michael Liu, MJL Manager (SNGX) disclose 983,588 shares; related group holds material blocks", "summary": "Michael Liu, MJL Manager LLC, and Capuchin Capital Fund LP have disclosed their beneficial ownership of SOLIGENIX, INC. (SNGX) shares via a Schedule 13G filing. Michael Liu reports beneficial ownership of 983,588 shares (5.7%), while MJL Manager LLC holds 893,588 shares (5.2%), a", "url": "https://www.stocktitan.net/sec-filings/SNGX/schedule-13g-soligenix-inc-passive-investment-disclosure-5-deb7c3dfdae9.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:32", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix, Inc. Actuals & Estimates (NASDAQ:SNGX)", "summary": "This article provides a detailed financial overview and analyst estimates for Soligenix, Inc. (NASDAQ:SNGX), covering its stock price performance, forecasts, historical highs and lows, volatility, market capitalization, earnings, and revenue. It also addresses frequently asked qu", "url": "https://www.tradingview.com/symbols/NASDAQ-SNGX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:40:44", "published_display": "25 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNGX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Soligenix, Inc. (SNGX) stock for 2027, based on analyst opinions. It includes financial data, past performance, and answers frequently asked questions about the company's stock, such as its current price, volatility, market ca", "url": "https://www.tradingview.com/symbols/NASDAQ-SNGX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:40:32", "published_display": "25 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Soligenix, Inc. \u2013 NASDAQ:SNGX", "summary": "The article mentions the enterprise value to revenue forward for Soligenix, Inc. (NASDAQ: SNGX). It appears to be a financial data point from TradingView, which often provides various financial metrics for stocks. The content indicates this specific metric is related to Soligenix", "url": "https://www.tradingview.com/symbols/NASDAQ-SNGX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T13:11:48", "published_display": "25 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Inc (SNGX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Soligenix Inc (SNGX) stock information, focusing on its dividend history and stock split events. It highlights that the company has not distributed dividends in the past five years and details several merger-related stock splits, primarily in ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sngx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-21T21:09:13", "published_display": "21 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Inc (SNGX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Soligenix Inc (SNGX), highlighting its current earnings forecast score of 8.00 and an average price target of $17.50, based on one analyst's \"Buy\" rating. It details the upside potential, recent EPS performance, and expected next-qua", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sngx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T13:10:40", "published_display": "18 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Inc (SNGX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Soligenix Inc (SNGX), noting its current financial score is 6.59, ranking 238 out of 388 in the Biotechnology & Medical Research industry. It identifies the company's financial status as robust but its operating efficiency as low. Cru", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sngx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:49", "published_display": "18 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Inc (SNGX) Institutional Confidence", "summary": "This article provides an overview of the institutional confidence in Soligenix Inc (SNGX), noting its stock price, market cap, and various financial scores from TradingKey. It details institutional shareholding and shareholder activity, highlighting changes in shares held by seve", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sngx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T00:10:12", "published_display": "17 Jun 2026 00:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNGX - Soligenix Inc Stock Price and Quote", "summary": "This page provides a detailed financial overview and news compilation for Soligenix Inc. (SNGX), a late-stage biopharmaceutical company focusing on rare diseases. It includes stock performance data, key financial metrics, recent analyst ratings, and a chronological list of news e", "url": "https://finviz.com/stock?t=SNGX", "source_name": "Finviz", "published_at": "2026-06-16T11:11:32", "published_display": "16 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix's Richard C. Straube ceases Consulting CMO role; duties moved to Christopher Pullion", "summary": "Richard C. Straube has ended his role as Consulting Chief Medical Officer for Soligenix on June 11, 2026. His responsibilities have been transferred to Medical Director Christopher Pullion. This change occurred due to the company's decision to terminate its HyBryte\u2122 development p", "url": "https://www.tradingview.com/news/tradingview:9b7b379d5df25:0-soligenix-s-richard-c-straube-ceases-consulting-cmo-role-duties-moved-to-christopher-pullion/", "source_name": "TradingView", "published_at": "2026-06-12T20:09:14", "published_display": "12 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Received Notice of Noncompliance", "summary": "Soligenix (SNGX) received a notice from Nasdaq on June 10, 2026, indicating noncompliance with the minimum bid price requirement for having its stock trade below $1.00 for 30 consecutive business days. The company has 180 days, until December 7, 2026, to regain compliance, with a", "url": "https://www.tradingview.com/news/tradingview:1e5416fa10a7b:0-soligenix-received-notice-of-noncompliance/", "source_name": "TradingView", "published_at": "2026-06-12T20:09:13", "published_display": "12 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix (NASDAQ: SNGX) faces Nasdaq bid-price risk and ends HyBryte program", "summary": "Soligenix (NASDAQ: SNGX) announced the termination of its HyBryte\u2122 development program following an interim analysis of its Phase 3 trial that recommended stopping due to futility, resulting in an estimated $70,000 in wind-down costs. Concurrently, the company received a Nasdaq w", "url": "https://www.stocktitan.net/sec-filings/SNGX/8-k-soligenix-inc-reports-material-event-f9a176781f43.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:13", "published_display": "12 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 8, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Stock Short Interest Rises to 43.99%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNLXBicmxhclFTUXZZbERRSWU3SnB2Smh5aWpndzhheWdUbjNadUEzd1lZcEI0amUwLWR1X3p2MmVyNXVUUTFzcHRvMUVFVUtCRjY2ZnNqT0VIbUJnVFlYRXEzSUotdlNsN1NtUEQ3LXltM0FXcGU0anpmNk1pS3lNdVg2YXJJek9M?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine", "summary": "Soligenix, Inc. is applying for vaccine development funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for a Bundibugyo virus (BDBV) vaccine. The company, in collaboration with Dr. Axel Lehrer of the University of Hawai\u02bbi at M\u0101noa, has developed thermostable ", "url": "https://www.prnewswire.com/news-releases/soligenix-applying-for-vaccine-development-funding-for-bundibugyo-ebola-vaccine-302793388.html", "source_name": "PR Newswire", "published_at": "2026-06-08T11:39:17", "published_display": "08 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Expands At-The-Market Equity Financing Capacity", "summary": "Soligenix, a biopharmaceutical company, has increased its At-The-Market (ATM) equity financing capacity by an additional $2,956,000, following previous sales of approximately $3,445,000 under the same program. This move allows Soligenix greater financial flexibility for its opera", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SNGX/pressreleases/2210014/soligenix-expands-at-the-market-equity-financing-capacity/", "source_name": "The Globe and Mail", "published_at": "2026-05-31T07:40:54", "published_display": "31 May 2026 07:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix, Inc. Files SEC Form 8-K for May 28, 2026 \u2013 Company Information and Legal Exhibits", "summary": "Soligenix, Inc. filed an 8-K with the SEC announcing an increase in its At Market Issuance Sales Agreement with Rodman & Renshaw LLC by $2,956,000, bringing the total to $6,406,000. This move, approved by the Board of Directors, aims to raise capital but also introduces potential", "url": "https://www.minichart.com.sg/2026/05/29/soligenix-inc-files-sec-form-8-k-for-may-28-2026-company-information-and-legal-exhibits/", "source_name": "Minichart", "published_at": "2026-05-29T14:39:42", "published_display": "29 May 2026 14:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix (NASDAQ: SNGX) raises at-the-market stock capacity by $2.96M", "summary": "Soligenix (NASDAQ: SNGX) has increased its at-the-market stock offering capacity by an additional $2.96 million through a prospectus supplement. This expands an existing sales agreement with Rodman & Renshaw LLC, under which the company had previously sold approximately $3.445 mi", "url": "https://www.stocktitan.net/sec-filings/SNGX/8-k-soligenix-inc-reports-material-event-01d174282f19.html", "source_name": "Stock Titan", "published_at": "2026-05-28T21:38:57", "published_display": "28 May 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix (NASDAQ: SNGX) raises ATM ceiling to $2.96M under Sales Agreement", "summary": "Soligenix, Inc. has updated its at-the-market (ATM) offering capacity to $2.96 million for common stock under a Sales Agreement with Rodman & Renshaw LLC. This adjustment is based on a public float of $24.51 million and aligns with General Instruction I.B.6 of Form S-3. The compa", "url": "https://www.stocktitan.net/sec-filings/SNGX/424b5-soligenix-inc-prospectus-supplement-debt-securities-38724fd96b27.html", "source_name": "Stock Titan", "published_at": "2026-05-28T21:38:57", "published_display": "28 May 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix raises at\u2011market share capacity by $2.956M under sales agreement", "summary": "Soligenix (SNGX) has increased the maximum amount of common stock available for sale under its at-market sales agreement by $2,956,000. This follows a prospectus supplement filed on May 28, 2026. The company had previously sold approximately $3,445,000 of common stock under the s", "url": "https://www.tradingview.com/news/tradingview:d789be717e178:0-soligenix-raises-at-market-share-capacity-by-2-956m-under-sales-agreement/", "source_name": "TradingView", "published_at": "2026-05-28T21:38:57", "published_display": "28 May 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Soligenix (SNGX.US)$ small win but consistent so far.", "summary": "An investor, Delmas W, shared a brief post on the Moomoo community platform noting a \"small win but consistent so far\" with Soligenix (SNGX.US). The post was part of a discussion thread titled \"Share Your Profit/Loss.\" The content itself is very minimal, serving more as a comment", "url": "https://www.moomoo.com/community/feed/soligenix-sngx-us-small-win-but-consistent-so-far-116648049311749", "source_name": "Moomoo", "published_at": "2026-05-28T05:39:44", "published_display": "28 May 2026 05:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix more than doubles as traders react to Ebola-outbreak vaccine-platform update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNU0Q3UXpIR0J4M08xOXhoSmVWYVdiRWZSYUc0SmQ5UW5SUGQyWjlKQTlYVTIybEk2WWtmYzl0aUFpY2I2YTJYS1pqSFNOMVdlZUJCUnBjNHk0YkJyV2FEb042R3JESHlUbk1DZmhMbzQ2OTR2TEd1b1kyTEcxQkRWZDNSRDNvYWlFcHFacTJBeWFYempWQWQ3bVZsUktQRzJBWlBNUkRRSzItZ3JWZ2NWWTFTTjYzYTFPazY4?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Announces Recent Updates and First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/soligenix-announces-recent-updates-first-113000061.html", "source_name": "PR Newswire", "published_at": "2026-05-08T11:30:00+00:00", "published_display": "08 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte\u2122 in Treatment of Cutaneous T-Cell Lymphoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/soligenix-announces-interim-results-phase-113000458.html", "source_name": "PR Newswire", "published_at": "2026-04-28T11:30:00+00:00", "published_display": "28 Apr 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial \u2014 Traders Eye Multiday Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQTGoxWFZIWEdHUFZlc3QwYnAzQ2oySUpsU2JXMncxWjhMLUJrUm9HajNORVEtM2lqREJjRTF1NkRjLVFtMGlrcHlyd3h3VmxTajdlQ0ZjQ3MyeHVCWjdqNjlkUURPMVBSVGF3UXFXNF9OWlhsR3pBTUxzS0JKa2FOeDBMRVNFR0hDdnFfUUNZNV9OdExIMjJNN2J4WG1nSUd3bHhkLW4taVdmTGgxYUg3cDNiN0NpS2dHZEhhcnJrV0ZiVmg3WkEwTGJFRGdhQnJEd2V6THZGd1FtWmI5ejQ4?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix Announces Pricing of $7.5 Million Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPMlVTVE1xR0JJSlh4bWNVV2djVmNCcHBQM29fc3lvamctYnM5NFZPZjhmMkVYMmZRZWF1ajFzNE9rQVlXaldrYTZOWV82M0laZkpySUZQZTF2U3FVWGdDdmVVZy1PVjRXWG45WG9XVW9fWUY0X0hCUFJrLVFBWmk3WnNST0N0c01pVHFLQmhybk1tckctMnlUd3drMmk3bUE4ZUdHRmFaZHBnSU1YTHNZOGRlZU4?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-26T07:00:00+00:00", "published_display": "26 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNaldSR2VuTFVVbTBaY0pSWlI0RFdoLXVTNi1jaDh3cXZSdGJLWk5QMXJWRDhaZERXRXAxZHB6VThXWDgxTVJzV0lRYlJyMGJNN29jM1lySmZObElBQkhtOVo3M1hMWEV3enU0dUR3bjlfcGxQRGZNYURZYm9xemM3VFRsdzB4NW5Gc0tF?oc=5", "source_name": "Market source", "published_at": "2025-08-20T07:00:00+00:00", "published_display": "20 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soligenix (SNGX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9LZjZrcURQeHRDMXcwdWxwZkFsQjZ6SWxRVzlPU1NJR3pUb0poa2tLTHJhbVFnSmc5V2IwYy1Kdm5rLXVXSkRoV3lOUUYwVDgzR1VJ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:42:21+00:00", "published_display": "25 Apr 2025 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 45, "sentiment_summary": {"positive": 5, "negative": 9, "neutral": 31, "score": 48, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 14.3, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 7.56, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 0.36, "latest_week": "2026-07-17", "one_week_move": -0.3, "four_week_move": -10.1, "twelve_week_move": -74.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.471602, "market_dynamics_buy_signal": false, "relative_strength": -77.375714, "fair_value_gap": -91.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.3391, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.3% over one week, -10.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 51, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 10}, {"label": "Stock Titan", "count": 8}, {"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 4}, {"label": "PR Newswire", "count": 4}, {"label": "The Globe and Mail", "count": 2}, {"label": "Quiver Quantitative", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 36}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "36", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.3% over one week, -10.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Soligenix (SNGX) seeks reverse stock split, higher share authorization to protect Nasdaq listing"}], "updated_at": "2026-07-22T22:35:05.158573+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}